Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Life Technologies, TGen and US Oncology partner on breast cancer sequencing
April 2010
SHARING OPTIONS:

CARLSBAD, Calif.Life Technologies Corp., the Translational Genomics Research Institute (TGen) and US Oncology have partnered on a project to sequence the genomes of 14 patients afflicted with triple-negative breast cancer whose tumors have progressed despite multiple other therapies, the companies announced in March. The goal of the collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals. US Oncology will help enroll patients in the study to have both tumor and healthy tissue sequenced using Applied Biosystems' SOLiD system to identify mutations, which will be validated by CLIA-certified Caris Life Sciences. Scientists from TGen and Life Technologies will develop computational and informatics software to query, identify and interpret mutations from whole-genomic sequencing data.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.